Major Program
US-Latin American-Caribbean U54
Sponsor
Weill Medical College of Cornell University
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04255849
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult cisgender men and transgender women living with HIV.
Intervention
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo
Condition
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
Investigators
Timothy Wilkin, MD, MPH